This message was posted by a user wishing to remain anonymous
Hello, Appreciate input on this -- is there FDA or ICH guideline or position paper or presentation specifying that overall process yield need to be monitored as a part of IPCs or during PPQ/Process Validation?
For biologics (monoclonal antibodies) or small molecules.
thanks